[Eighteen years' experience of thrombolytic therapy with streptokinase (author's transl)].
18 years clinical experience with thrombolytic therapy has shown that venous and arterial thrombotic occlusions which persist not only for a few days but also for weeks and 2 to 4 months can be dissolved in about 60-70% of the cases by intravenous infusion of streptokinase. Although this treatment is one of the great break-throughs of internal medicine in this century it is not yet in general use. The reason for this is that the risk of a deleterious bleeding is difficult to assess. This and also the numerous contraindications can be diminished by direct infiltration of an intravasal clot with a relatively small amount of streptokinase through a catheter.
D001161:Arteriosclerosis / Q000188:drug therapy; D001809:Blood Viscosity / Q000187:drug effects; D005334:Fever / Q000139:chemically induced; D005342:Fibrinolysis / Q000187:drug effects*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D011655:Pulmonary Embolism / Q000188:drug therapy; D013300:Streptokinase / Q000009:adverse effects / Q000627:therapeutic use*; D013919:Thromboangiitis Obliterans / Q000188:drug therapy; D013924:Thrombophlebitis / Q000188:drug therapy; D013927:Thrombosis / Q000188:drug therapy*
D013300:Streptokinase
18 Jahre thrombolytische Therapie mit Streptokinase. 19H